NASDAQ:WVE WAVE Life Sciences (WVE) Stock Price, News & Analysis $7.35 +0.16 (+2.23%) Closing price 10/8/2025 04:00 PM EasternExtended Trading$7.40 +0.05 (+0.68%) As of 04:33 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock About WAVE Life Sciences Stock (NASDAQ:WVE) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get WAVE Life Sciences alerts:Sign Up Key Stats Today's Range$7.11▼$7.4050-Day Range$6.66▼$10.1552-Week Range$5.28▼$16.74Volume4.70 million shsAverage Volume1.79 million shsMarket Capitalization$1.17 billionP/E RatioN/ADividend YieldN/APrice Target$20.33Consensus RatingModerate Buy Company Overview WAVE Life Sciences is a clinical-stage genetic medicines company focused on the discovery and development of stereopure oligonucleotide therapies designed to address serious diseases with high unmet medical need. Leveraging proprietary chemistry and precision synthesis, WAVE engineers drug candidates with defined stereochemistry to optimize potency, safety and manufacturability. This approach aims to enhance target specificity and improve therapeutic profiles compared with traditional oligonucleotide medicines. The company’s pipeline includes programs in neuromuscular disorders such as Duchenne muscular dystrophy and neurodegenerative conditions including Huntington’s disease, as well as early-stage cardiovascular and liver indications. Several assets are advancing through preclinical research and clinical trials, and WAVE collaborates with biopharmaceutical partners to co-develop selected candidates and expand the reach of its technology into new disease areas. WAVE’s research and development activities are anchored in its laboratories in Cambridge, Massachusetts, where multidisciplinary teams of chemists, biologists and clinical scientists work to translate novel oligonucleotide designs into development candidates. The company also maintains strategic collaborations and research partnerships in North America and Asia, aiming to accelerate global access to its therapies and support regulatory filings in multiple jurisdictions. Founded in 2015, WAVE Life Sciences has built a leadership team with deep expertise in RNA biology, medicinal chemistry and drug development. The company continues to refine its stereopure oligonucleotide platform to address delivery challenges, improve pharmacokinetics and expand its pipeline across a broad range of genetic and rare diseases.AI Generated. May Contain Errors. Read More WAVE Life Sciences Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks89th Percentile Overall ScoreWVE MarketRank™: WAVE Life Sciences scored higher than 89% of companies evaluated by MarketBeat, and ranked 105th out of 942 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.4 / 5Analyst RatingModerate Buy Consensus RatingWAVE Life Sciences has received a consensus rating of Moderate Buy. The company's average rating score is 2.81, and is based on 14 buy ratings, 1 hold rating, and 1 sell rating.Upside PotentialWAVE Life Sciences has a consensus price target of $20.33, representing about 176.6% upside from its current price of $7.35.Amount of Analyst CoverageWAVE Life Sciences has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about WAVE Life Sciences' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for WAVE Life Sciences are expected to grow in the coming year, from ($1.14) to ($1.06) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of WAVE Life Sciences is -8.17, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of WAVE Life Sciences is -8.17, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioWAVE Life Sciences has a P/B Ratio of 5.36. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about WAVE Life Sciences' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted11.34% of the outstanding shares of WAVE Life Sciences have been sold short.Short Interest Ratio / Days to CoverWAVE Life Sciences has a short interest ratio ("days to cover") of 9.8.Change versus previous monthShort interest in WAVE Life Sciences has recently increased by 4.16%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldWAVE Life Sciences does not currently pay a dividend.Dividend GrowthWAVE Life Sciences does not have a long track record of dividend growth. Sustainability and ESG4.8 / 5Environmental Score-0.58 Percentage of Shares Shorted11.34% of the outstanding shares of WAVE Life Sciences have been sold short.Short Interest Ratio / Days to CoverWAVE Life Sciences has a short interest ratio ("days to cover") of 9.8.Change versus previous monthShort interest in WAVE Life Sciences has recently increased by 4.16%, indicating that investor sentiment is decreasing. News and Social Media1.9 / 5News Sentiment0.45 News SentimentWAVE Life Sciences has a news sentiment score of 0.45. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.63 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for WAVE Life Sciences this week, compared to 6 articles on an average week.Search Interest15 people have searched for WVE on MarketBeat in the last 30 days. This is an increase of 67% compared to the previous 30 days.MarketBeat FollowsOnly 4 people have added WAVE Life Sciences to their MarketBeat watchlist in the last 30 days. This is a decrease of -20% compared to the previous 30 days. Company Ownership4.2 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, WAVE Life Sciences insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $2,423,068.00 in company stock.Percentage Held by Insiders23.98% of the stock of WAVE Life Sciences is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions89.73% of the stock of WAVE Life Sciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about WAVE Life Sciences' insider trading history. Receive WVE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for WAVE Life Sciences and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. WVE Stock News HeadlinesCanaccord Genuity Keeps Their Buy Rating on Wave Life Sciences (WVE)October 7 at 8:47 AM | theglobeandmail.comWave Life Sciences (WVE) Receives a Buy from Leerink PartnersOctober 7 at 8:47 AM | theglobeandmail.comCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holding investments longer to using tax-advantaged accounts and strategic loss offsetting, there are ways to reduce your exposure. SmartAsset outlines three capital gains tax strategies for seniors and offers a free tool to connect you with vetted fiduciary financial advisors who can help tailor these tactics to your situation. | SmartAsset (Ad)Invivyd appoints Wave Life Sciences CEO Paul Bolno to boardSeptember 25, 2025 | msn.comWave Life Sciences Highlights WVE-007 Obesity TreatmentSeptember 25, 2025 | msn.comWave Life Sciences Announces Virtual Research Day on October 29th and Participation at Upcoming Investor ConferencesSeptember 18, 2025 | globenewswire.comWave Life Sciences (WVE) Sees Promising Results From RestorAATion-2 StudySeptember 10, 2025 | finance.yahoo.comRaymond James Reaffirms Their Buy Rating on Wave Life Sciences (WVE)September 9, 2025 | theglobeandmail.comSee More Headlines WVE Stock Analysis - Frequently Asked Questions How have WVE shares performed this year? WAVE Life Sciences' stock was trading at $12.37 on January 1st, 2025. Since then, WVE stock has decreased by 40.6% and is now trading at $7.35. How were WAVE Life Sciences' earnings last quarter? WAVE Life Sciences Ltd. (NASDAQ:WVE) issued its quarterly earnings data on Wednesday, July, 30th. The company reported ($0.31) EPS for the quarter, missing analysts' consensus estimates of ($0.29) by $0.02. The company earned $8.70 million during the quarter, compared to analysts' expectations of $11.52 million. Read the conference call transcript. How do I buy shares of WAVE Life Sciences? Shares of WVE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of WAVE Life Sciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that WAVE Life Sciences investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Meta Platforms (META), Tesla (TSLA), JPMorgan Chase & Co. (JPM), Intel (INTC) and Netflix (NFLX). Company Calendar Last Earnings7/30/2025Today10/09/2025Next Earnings (Estimated)11/11/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:WVE CIK1631574 Webwww.wavelifesciences.com Phone(656) 236-3388Fax617-949-2901Employees240Year Founded2012Price Target and Rating Average Price Target for WAVE Life Sciences$20.33 High Price Target$36.00 Low Price Target$10.00 Potential Upside/Downside+176.6%Consensus RatingModerate Buy Rating Score (0-4)2.81 Research Coverage16 Analysts Profitability EPS (Trailing Twelve Months)($0.90) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$97.01 million Net MarginsN/A Pretax Margin-138.24% Return on Equity-78.45% Return on Assets-41.51% Debt Debt-to-Equity RatioN/A Current Ratio2.56 Quick Ratio2.56 Sales & Book Value Annual Sales$108.30 million Price / Sales10.80 Cash FlowN/A Price / Cash FlowN/A Book Value$1.37 per share Price / Book5.36Miscellaneous Outstanding Shares159,140,000Free Float120,978,000Market Cap$1.17 billion OptionableOptionable Beta-1.37 Social Links The Best High-Yield Dividend Stocks for 2025Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free Report This page (NASDAQ:WVE) was last updated on 10/9/2025 by MarketBeat.com Staff From Our PartnersBitcoin grabs headlines, but smart money likes this tokenBitcoin grabs headlines, but smart money likes this token My research team has identified the token positio...Crypto 101 Media | SponsoredMagnificent 7 being replaced by the “Hidden 7”?BULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | SponsoredAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...Porter & Company | SponsoredREVEALED: Something Big Happening Behind White House DoorsWhat I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | Sponsored$3,600 gold is nice ... but here’s what most gold bugs are missingGold just surged past $3,600, but Weiss Ratings expert Sean Brodrick says the real upside is in select gold st...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding WAVE Life Sciences Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share WAVE Life Sciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.